HPV Testing & Pap Test Market

The Global HPV Testing & Pap Test Market is projected to reach the US $ 4.52 billion, at a CAGR of 6.6%

The Research report provides a detailed overview of Several factors such as increasing number of cervical cancer cases, growing aging population, increasing awareness of cervical cancer screening programs, and government initiative and funding are propelling the growth of the HPV testing and Pap test market.

However, changes in regulatory guidelines for cervical cancer screening and HPV vaccination are some major factors restraining the growth of this market. HPV contributes to around 90% of all anal and cervical cancers and 70% of vaginal and vulvar cancers. Pap tests are the most preferred tests to detect cervical cancer.

Download PDF (HPV Testing and Pap Test Market):

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=214207371

the uncertain reimbursement scenario serves to be a major challenge impacting the growth of the HPV test and Pap test market.

The increasing number of cervical cancer cases and the ing aging population

Cervical cancer is considered to be the fourth most prevalent forms of cancer globally and is the most common cause of death among women (Source: Global Cancer Facts and figures). It has been estimated that 527,624 new cases of cervical cancer have emerged worldwide, while 265,653 women died due to cervical cancer in 2012.

This figure is expected to reach to 609,270 new cases and 315,727 deaths by 2020. (Source: Globocan 2012). Approximately 26,000 new cancers attributable to HPV occur each year, 18,000 among females and 8,000 among males (Source: CDC). The growing number of cervical cancer cases results in the need for new, technically advanced, and less expensive screening programs. This, in turn, is expected to drive the HPV testing and Pap test market in the coming years.

HPV Testing & Pap Test Market segmentation:

· based on products

· based on diseases

· based on techniques,

· based on end users

· based on regions.

The Major Players Operating in the HPV Testing & Pap Test Market:

Abbott Laboratories (U.S.), Qiagen N.V. (The Netherlands), Hologic Inc. (U.S.), Roche Diagnostics (Switzerland), Quest Diagnostics (U.S.), Becton, Dickinson, and Company (U.S.) are the key players operating in the HPV testing and Pap test market.

Speak to Our Subject Expert (HPV Testing and Pap Test Market):

https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=214207371

Major Developments in HPV Testing & Pap Test Market

In April 2014, Roche received the U.S. FDA approval for its cobas HPV (Human Papillomavirus) Test, which is used as a first-line primary screening test for cervical cancer in women.
In February 2014, BD Diagnostics received the CE/IVD marking for the BD Onclarity HPV Assay that can be used on the new BD Viper LT System
In September 2015, QIAGEN introduced careHPV Test and digene HC2 Collection Device for the HPV screening process in women.
IN February 2014, QIAGEN expanded commercial launch of careHPV test in India, a molecular diagnostic test for high risk human papillomavirus (HPV), a primary cause of cervical cancer in woman.

Geographical Detailed Analysis for HPV Testing & Pap Test Market:

Geographically, the HPV testing and Pap test market are segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW).

North America is expected to grow at the highest CAGR in the forecast period. Increased government funding & grants and an introduction of HPV primary tests are major factors fueling the growth of the HPV testing and Pap test market in North America.

Request Research Sample Pages (HPV Testing & Pap Test Market):

https://www.marketsandmarkets.com/requestsampleNew.asp?id=214207371